Recently, Tianjin Silkar Biotech Co., Ltd., a company initiated by Fosun Health Capital New Drug Innovation Fund and invested by Tianjin Fosun Haihe Medical and Healthcare Industry Fund Partnership, has officially opened its GMP factory.
Silkar Biotech is a science and technology enterprise specialising in the development, production and promotion of high-end medical aesthetic products. Since its inception, Silkar Biotech has been developing and manufacturing medical aesthetic products based on the medical aesthetic track, using silk fibroin as the main raw material. “The opening of the GMP factory is an important milestone in the development of Silkar Biotech, and it marks another important step forward in the product registration process”, said Huansheng Zhao, Executive President of Silkar Biotech.
This year, Silkar Biotech was recognised as a ‘Small and Medium Sci-tech Enterprise’ and a ‘Gazelle Enterprise’ in Tianjin. The accreditation of Small and Medium Sci-tech Enterprises and Gazelle enterprises is a high recognition of the company's innovative ability and technological strength. Silkar Biotech's innovative silk fibroin regenerative medical products are expected to overturn the traditional medical aesthetic injectable filler market, of which the gel pipeline is expected to carry out clinical trials by the end of this year.
Fosun Health Capital New Drug Innovation Fund is the first incubation fund focusing on innovative biopharmaceuticals under Fosun Pharma. Relying on Fosun Pharma's overseas vision and FOF layout, the fund is committed to landing overseas high-quality world-class biotechnology and products in China through introduction and cooperation, and realising breakthroughs in innovative pharmaceutical products from 0 to 1 by sensing the trend of cutting-edge technology and linking biopharmaceutical industry resources and top scientists teams at home and abroad.
Tianjin Fosun Haihe Medical and Healthcare Industry Fund Partnership (Limited Partnership), jointly funded by Fosun Pharma, Haihe Industry Fund and Tianjin Port Free Trade Zone, was registered in 2020 in the Free Trade Zone, with a total scale of RMB 500 million, and its main investment direction is biomedical industry. Up to now, the fund has invested in 10 enterprises, covering the fields of medical aesthetics, targeted drugs, cell therapy, etc.
In the future, Tianjin Port Free Trade Zone will deeply implement the spirit of the Third Plenary Session of the 20th CPC Central Committee, closely focus on the national strategy, better play the role of the government investment fund, make patient capital, create a regional industrial mother fund and new quality productivity industry direction sub-fund equity investment fund system, promote the integration of capital investment and scientific and technological innovation, industrial innovation, and vigorously develop the low-altitude economy, bio-manufacturing, green hydrogen energy, gene technology and other four future industries. technology and other four future industries, contributing to the high-quality development of Tianjin.
Copyright ©2020 www.suhaobio.com.cn, All Rights Reserved
Jiangsu lCP No. 19075400-1 Jiangsu Computer Information Network and internet unit registration No. 32050602011157 Qualification Certificate for Medicine Trading Services on the Internet:(Jiangsu)-Non-Operating-2020-0041